Skip to main content
Publications
Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Can C, Chassot-Agostinho A, Reynolds M, Odom D, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the phase II GEOMETRY mono-1 study. Poster presented at the ASCO 2021 Annual Meeting; June 4, 2021.
Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7
Richardson D, Zhan L, Reynolds M, Odom D, Hollis K, Mitra D, McRoy L, Hargis J. The impact of advanced or metastatic breast cancer or its treatment on productivity, energy, and physical activity among palbociclib participants of the MADELINE Study. Poster presented at the Virtual 12th European Breast Cancer Conference; October 2, 2020.